The Genecept Assay® is a genetic test used to inform clinicians’ decision-making when prescribing medications and treatments for psychiatric conditions.
Genetic results provide information about the likelihood that a patient will respond to a medication therapy and/or experience adverse events or drug interactions. Treatment decisions informed by these genetic results can offer a personalized treatment plan to objectively address presenting symptoms and side effects. The genes analyzed in the Genecept Assay® are associated with a wide range of psychotropic medications and can help to inform treatment plans for depression, anxiety, obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), bipolar disorder, post traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse.
This personalized, data-driven approach, which is pain-free and simple to perform, can reduce the time, expense and struggle of finding the right treatment by trial and error.
For patients with major depression, antidepressant medication is commonly the first treatment.
In addition, our PAKC physicians are offering another promising non-invasive treatment. In 2008, the FDA approved the use of Transcranial Magnetic Stimulation (TMS) in certain cases where patients have not responded to antidepressant medication.
Research has found that stimulation of neuromuscular tissue can help in treatment of some cases of depression. TMS uses magnetic waves to stimulate or inhibit nerve response, and induce electrical currents in target sections of the cortex, spinal roots and peripheral nerves.
We are one of the first psychiatric practices in the region to offer TMS treatments for depression. This leading-edge approaches require specialized expertise and equipment, which is offered at our dedicated suite at our Leawood location.
APSKC is currently offering ketamine infusions for Treatment Resistant Depression. When effective, ketamine may alleviate depressive symptoms within a matter of hours or days. Ketamine received Food and Drug Administration (FDA) approval for use as an anesthetic in 1970. Ketamine has been well-studied for more than ten years an “off-label” procedure for treating depression. Off-label means that while the Food and Drug Administration (FDA) has not approved Ketamine as a safe and effective treatment for depression, it is both ethical and legal for trained and licensed professionals to administer ketamine for depression based on research evidence and clinical experience compiled since its approval as an anesthetic. Before the opening of the APSKC Ketamine Clinic in December 2016, Kansas City area patients sought ketamine treatments in clinics on the East and West Coasts, Denver, Texas, and other distant locations. After extensive review and discussion of the subject, our group made the commitment to providing the highest levels of effective and safe administration of ketamine for depression, including mechanisms for monitoring patient progress and modifying our treatment protocols, as the state-of-the-art progresses.